| Jonathan Hoyt Zarley, MD | |
|
222 Tongass Dr, Sitka, AK 99835-9416 | |
| (907) 966-2411 | |
| (907) 966-8300 |
| Full Name | Jonathan Hoyt Zarley |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 34 Years |
| Location | 222 Tongass Dr, Sitka, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659586832 | NPI | - | NPPES |
| MD3173 | Medicaid | AK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 3173 (Alaska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Hawaii Community Hospital | Kamuela, HI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Midpacific Hospitalists, Llc | 9335439926 | 14 |
| Queen's North Hawaii Community Hospital | 0143116293 | 58 |
News Archive
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.
Novan, Inc. today announced that the first patient has been dosed in its Phase 3 program to evaluate the efficacy and safety of its topical nitric oxide product candidate SB204 Gel in the treatment of acne vulgaris ("acne"). The Company is running two identically designed Phase 3 pivotal trials in parallel and expects to report top-line results in the first half of 2017.
UCSF and SEEK Development, a global health and development consulting group based in Berlin, Germany, have launched an international partnership that aims to improve global health by helping to turn scientific evidence into policy and action. The Evidence-to-Policy Initiative, or E2Pi, officially launches this week in San Francisco and Berlin, Germany.
Metrohm is the market leader for ion analysis. Analytica is the most important trade show for us on a global scale.
As part of the University Health Network, renowned cardiologist Dr. Heather Ross has launched a new clinical study, in collaboration with Apple to test if remote monitoring with Apple Watch can help with early identification of worsening heart failure.
› Verified 2 days ago
| Entity Name | Queen's North Hawaii Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528049814 PECOS PAC ID: 0143116293 Enrollment ID: O20040225000562 |
News Archive
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.
Novan, Inc. today announced that the first patient has been dosed in its Phase 3 program to evaluate the efficacy and safety of its topical nitric oxide product candidate SB204 Gel in the treatment of acne vulgaris ("acne"). The Company is running two identically designed Phase 3 pivotal trials in parallel and expects to report top-line results in the first half of 2017.
UCSF and SEEK Development, a global health and development consulting group based in Berlin, Germany, have launched an international partnership that aims to improve global health by helping to turn scientific evidence into policy and action. The Evidence-to-Policy Initiative, or E2Pi, officially launches this week in San Francisco and Berlin, Germany.
Metrohm is the market leader for ion analysis. Analytica is the most important trade show for us on a global scale.
As part of the University Health Network, renowned cardiologist Dr. Heather Ross has launched a new clinical study, in collaboration with Apple to test if remote monitoring with Apple Watch can help with early identification of worsening heart failure.
› Verified 2 days ago
| Entity Name | Midpacific Hospitalists, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053778217 PECOS PAC ID: 9335439926 Enrollment ID: O20160610000376 |
News Archive
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.
Novan, Inc. today announced that the first patient has been dosed in its Phase 3 program to evaluate the efficacy and safety of its topical nitric oxide product candidate SB204 Gel in the treatment of acne vulgaris ("acne"). The Company is running two identically designed Phase 3 pivotal trials in parallel and expects to report top-line results in the first half of 2017.
UCSF and SEEK Development, a global health and development consulting group based in Berlin, Germany, have launched an international partnership that aims to improve global health by helping to turn scientific evidence into policy and action. The Evidence-to-Policy Initiative, or E2Pi, officially launches this week in San Francisco and Berlin, Germany.
Metrohm is the market leader for ion analysis. Analytica is the most important trade show for us on a global scale.
As part of the University Health Network, renowned cardiologist Dr. Heather Ross has launched a new clinical study, in collaboration with Apple to test if remote monitoring with Apple Watch can help with early identification of worsening heart failure.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jonathan Hoyt Zarley, MD 222 Tongass Dr, Sitka, AK 99835-9416 Ph: (907) 966-2411 | Jonathan Hoyt Zarley, MD 222 Tongass Dr, Sitka, AK 99835-9416 Ph: (907) 966-2411 |
News Archive
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.
Novan, Inc. today announced that the first patient has been dosed in its Phase 3 program to evaluate the efficacy and safety of its topical nitric oxide product candidate SB204 Gel in the treatment of acne vulgaris ("acne"). The Company is running two identically designed Phase 3 pivotal trials in parallel and expects to report top-line results in the first half of 2017.
UCSF and SEEK Development, a global health and development consulting group based in Berlin, Germany, have launched an international partnership that aims to improve global health by helping to turn scientific evidence into policy and action. The Evidence-to-Policy Initiative, or E2Pi, officially launches this week in San Francisco and Berlin, Germany.
Metrohm is the market leader for ion analysis. Analytica is the most important trade show for us on a global scale.
As part of the University Health Network, renowned cardiologist Dr. Heather Ross has launched a new clinical study, in collaboration with Apple to test if remote monitoring with Apple Watch can help with early identification of worsening heart failure.
› Verified 2 days ago
Mrs. Marilyn C Coruzzi, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 209 Moller Ave, Sitka Community Hospital, Sitka, AK 99835 Phone: 907-474-1722 Fax: 907-747-1755 | |
Julien Louise Naylor, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 222 Tongass Dr, Sitka, AK 99835 Phone: 907-966-2411 Fax: 907-966-8342 | |
Dr. Guillermo Eduardo Espinoza, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 222 Tongass Dr, Sitka, AK 99835 Phone: 907-966-2411 | |
Dr. Kimberly Christine Capp, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 222 Tongass Dr, Sitka, AK 99835 Phone: 907-966-2411 |